论文部分内容阅读
目的评价氨曲南对下呼吸道感染的临床疗效,探讨氨曲南临床应用价值。方法150例患者随机分为氨曲南(A组)和头孢拉啶(B组),每组75例。A组给予氨曲南注射用灭菌粉末2.0 g,B组给予头孢他啶注射用无菌粉末2.0 g,均加入氯化钠注射液250 mL中,静滴,每天1次,疗程为7～14 d,观察期间不加用其他抗生素。结果A、B组的临床有效率分别为88.00%、85.33%,二者比较差异无显著性(P>0.05)。A、B组的细菌清除率分别为90.91%、88.89%,二者比较差异无显著性(P>0.05)。在治疗中,A组有1例患者出现轻度恶心,有2例出现皮肤瘙痒;B组有3例出现轻度恶心,有1例出现轻度腹胀。停药后上述症状自行消失。结论氨曲南对大多数需氧革兰阴性菌具有高度的抗菌活性,适用于治疗敏感需氧革兰阴性菌所致的各种感染。
Objective To evaluate the clinical efficacy of aztreonam on lower respiratory tract infection and explore its clinical value. Methods 150 patients were randomly divided into aztreonam (group A) and cefradine (group B), 75 cases in each group. Group A was given Aztreonam sterile powder 2.0 g, B group was given ceftazidime sterile powder 2.0 g, were added sodium chloride injection 250 mL, intravenous infusion once a day for 7 to 14 d During the observation period, no other antibiotics were added. Results The clinical effective rates of group A and group B were 88.00% and 85.33% respectively, with no significant difference (P> 0.05). The bacterial clearance rates of A and B groups were 90.91% and 88.89% respectively, there was no significant difference between the two groups (P> 0.05). In the treatment group, 1 patient had mild nausea and 2 patients had itchy skin; 3 patients in group B had mild nausea and 1 patient had mild abdominal distension. After stopping the above symptoms disappear on their own. Conclusion Aztreonam has a high degree of antibacterial activity against most aerobic gram-negative bacteria and is suitable for treating various infections caused by sensitive aerobic gram-negative bacteria.